Formulation and Evaluation of Gastroretentive Dosage Forms of Clarithromycin

被引:0
|
作者
Muralidhar Nama
Chandra Sekhar Rao Gonugunta
Prabhakar Reddy Veerareddy
机构
[1] St. Peter’s Institute of Pharmaceutical Sciences,Pharmaceutics
[2] St. Peter’s Institute of Pharmaceutical Sciences,undefined
来源
关键词
clarithromycin; floating; HPMC; H.pylori; peptic ulcer;
D O I
暂无
中图分类号
学科分类号
摘要
The purpose of this research was to develop the hydrodynamically balanced delivery system of Clarithromycin (CLA) which, after oral administration should have the ability to prolong gastric residence time with the desired in vitro release profile for the localized action in the stomach, in the treatment of Helicobacter pylori (H.pylori) mediated peptic ulcer. By applying wet granulation technique floating tablets of Clarithromycin were prepared. The proportion of sodium bicarbonate was varied to get the least possible lag time, also the polymer part varied to get the desired release. In vivo radiographic studies were performed with Barium sulphate loaded formulation to justify the increased gastric residence time of the dosage form in the stomach, based on the floating principle. The formulation developed using 66.2% Clarithromycin, 12% HPMC K4M polymer, 8% sodium bicarbonate gave floating lag time less than 3 min with a floating time of 12 h, and an in vitro release profile very near to the desired release. X-ray studies showed the enhanced gastric residence time of the tablet to 220 ± 30 min. The mechanism of release of Clarithromycin from the floating tablets is anomalous diffusion transport and follows zero order kinetics. In vivo radiographic studies suggest that the tablet has increased gastric residence time for the effective localized action of the antibiotic (Clarithromycin) in the treatment of H.pylori mediated peptic ulcer.
引用
收藏
相关论文
共 50 条
  • [1] Formulation and evaluation of gastroretentive dosage forms of clarithromycin
    Nama, Muralidhar
    Gonugunta, Chandra Sekhar Rao
    Veerareddy, Prabhakar Reddy
    AAPS PHARMSCITECH, 2008, 9 (01) : 231 - 237
  • [2] Formulation and evaluation of clarithromycin gastroretentive dosage form
    Kadu, Pramod, 1600, Journal of Chemical and Pharmaceutical Research, 3/668 Malviya Nagar, Jaipur, Rajasthan, India (06):
  • [3] GASTRORETENTIVE DOSAGE FORMS
    MOES, AJ
    CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, 1993, 10 (02): : 143 - 195
  • [4] Formulation and Evaluation of a Gastroretentive Dosage Form of Labetalol Hydrochloride
    Garse, Harshal
    Vij, Mohit
    Yamgar, Manohar
    Kadam, Vilasrao
    Hirlekar, Rajashree
    ARCHIVES OF PHARMACAL RESEARCH, 2010, 33 (03) : 405 - 410
  • [5] Formulation and evaluation of a gastroretentive dosage form of labetalol hydrochloride
    Harshal Garse
    Mohit Vij
    Manohar Yamgar
    Vilasrao Kadam
    Rajashree Hirlekar
    Archives of Pharmacal Research, 2010, 33 : 405 - 410
  • [6] Expandable gastroretentive dosage forms
    Klausner, EA
    Lavy, E
    Friedman, M
    Hoffman, A
    JOURNAL OF CONTROLLED RELEASE, 2003, 90 (02) : 143 - 162
  • [7] In Vitro and In Vivo Test Methods for the Evaluation of Gastroretentive Dosage Forms
    Schneider, Felix
    Koziolek, Mirko
    Weitschies, Werner
    PHARMACEUTICS, 2019, 11 (08)
  • [8] Pharmacokinetic and pharmacodynamic aspects of gastroretentive dosage forms
    Hoffman, A
    Stepensky, D
    Lavy, E
    Eyal, S
    Klausner, E
    Friedman, M
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2004, 277 (1-2) : 141 - 153
  • [9] Gastroretentive dosage forms for prolonging gastric residence time
    Kumar R.
    Philip A.
    International Journal of Pharmaceutical Medicine, 2007, 21 (2) : 157 - 171
  • [10] Formulation of dosage forms
    Shangraw, RF
    IDEA TO PRODUCT: THE PROCESS, 1996, : 51 - 51